PALO ALTO, Calif., April 09, 2007 /PRNewswire-FirstCall/ -- Telik, Inc. announced that updated clinical data from its multicenter Phase 2 trial of the triplet combination of TELCYTA(R) (canfosfamide HCl, TLK286), carboplatin and paclitaxel will be presented at the 98th annual meeting of the American Association for Cancer Research (AACR) in Los Angeles. Preclinical studies of cellular and molecular correlates of synergistic cancer cell growth inhibition with TELCYTA in combination with standard chemotherapy, and studies describing TELCYTA's potential anti-angiogenic activity, also will be presented.
Details of the presentations are as follows: -- Phase 2 Multicenter Dose-Ranging Trial of TLK286 (Canfosfamide HCl) in Combination with Carboplatin and Paclitaxel as First-Line Treatment for Advanced Non-Small Cell Lung Cancer; Tuesday, April 17, 2007, 8:00 am - noon; Phase II-III Adult Clinical Trials; Abstract # 3521 -- Cellular and Molecular Correlates of Synergistic Growth Inhibition in Human Lung Cancer Cells by TLK286 (Canfosfamide HCl), a Novel Glutathione Analog Prodrug, in Combination with Paclitaxel and Carboplatin; Sunday, April 15, 2007, 8:00 am - noon; Drug Delivery I; Abstract # 1502 -- TLK286 (Canfosfamide HCl), a Novel Glutathione Analog Prodrug, Exhibits Antiangiogenic Effects Including the Inhibition of Human Endothelial Cell Proliferation and Capillary Tubule Formation In Vitro; Tuesday, April 17, 2007, 1:00 - 5:00 pm; Angiogenesis II: Novel Inhibitors; Abstract # 4622
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced drug development candidate is TELCYTA, a tumor-activated small molecule product candidate in clinical develo pment for the treatment of advanced ovarian cancer and non-small cell lung cancer. A second drug development candidate, TELINTRA(TM) (TLK199), is in clinical development in myelodysplastic syndrome. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(TM), which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com.
This press release contains "forward-looking" statements, including statements regarding the potential for TELCYTA to treat one or more types of cancer. There are important factors that could cause Telik's results to differ materially from those indicated by these forward-looking statements, including, among others, that none of Telik's product candidates have been determined to be safe or effective in humans or been approved for marketing, clinical trials of Telik's product candidates may take several years to complete and may not be successful, success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful and interim results of clinical trials do not necessarily predict final results. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Telik's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its annual report on Form 10-K for the year ended December 31, 2006. Telik does not undertake any obligation to update forward-looking statements contained in this press release.
NOTE: TELIK, the Telik logo, TELCYTA, TELINTRA and TRAP are trademarks or registered trademarks of Telik, Inc.
CONTACT: Carol D. DeGuzman, Senior Director, Corporate Communications ofTelik, +1-650-845-7728, or email@example.com
Web site: http://www.telik.com/
Ticker Symbol: (NASDAQ-NMS:TELK)
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company